MedTrace Logo

ImmuneSense COVID-19 Variant Study

NCT05054088 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 203

Last updated 2022-12-07

No results posted yet for this study

Summary

This study will assess the clinical performance of the T-Detect™ COVID test to identify an immune response to SARS-CoV-2 infection in the setting of multiple circulating variants of the SARS-CoV-2 virus. Performance may vary depending on the variants circulating at the time of testing, including newly emerging strains of SARS-CoV-2 and their prevalence, which changes over time.

Conditions

  • Covid19

Interventions

DEVICE

T-Detect COVID test

• The T-DetectTM COVID test is an EUA granted investigational device that is indicated to assess a T-cell immune response to SARS-CoV-2 via the testing of blood samples from patients with signs and symptoms of suspected COVID-19.

Sponsors & Collaborators

  • Adaptive Biotechnologies

    lead INDUSTRY

Principal Investigators

  • Darcy Gill, PhD · Adaptive Biotechnologies

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-12
Primary Completion
2022-07-20
Completion
2022-07-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05054088 on ClinicalTrials.gov